Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AAV9-mediated engineering of autotransplanted kidney of non-human primates.

Gene therapy·2017
Same author

Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Local gene therapy with indoleamine 2,3-dioxygenase protects against development of transplant vasculopathy in chronic kidney transplant dysfunction.

Gene therapy·2016
Same author

Local gene therapy with indoleamine 2,3-dioxygenase protects against development of transplant vasculopathy in chronic kidney transplant dysfunction.

Gene therapy·2016
Same author

Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy.

Minerva anestesiologica·2015
Same author

An unanticipated role for survivin in organ transplant damage.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014

Related Experiment Video

Updated: Jun 24, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

Endothelin receptor selectivity in chronic renal failure.

L Longaretti1, A Benigni

  • 1Mario Negri Institute for Pharmacological Research, Bergamo, Italy.

European Journal of Clinical Investigation
|April 2, 2009
PubMed
Summary

Treatments targeting endothelin-1 (ET-1) show promise for slowing chronic kidney disease progression. Further research is needed to determine the optimal use of endothelin receptor antagonists in renoprotection strategies.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

Related Experiment Videos

Last Updated: Jun 24, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

Area of Science:

  • Nephrology
  • Pharmacology
  • Cardiovascular Research

Background:

  • Chronic kidney diseases (CKD) represent a growing global health burden.
  • Endothelin-1 (ET-1) plays a significant role in renal physiology and pathology, contributing to vasoconstriction, inflammation, and fibrosis.
  • Elevated ET-1 levels correlate with CKD severity and impaired renal function.

Purpose of the Study:

  • To review the role of ET-1 in the pathogenesis of kidney diseases.
  • To evaluate the potential of endothelin receptor antagonists (ERAs) in renoprotection.
  • To discuss the optimal therapeutic strategies involving ET-1 antagonism for chronic nephropathies.

Main Methods:

  • Review of existing scientific literature on ET-1, CKD, and ERAs.
  • Analysis of studies investigating the effects of ERAs on renal hemodynamics and proteinuria.
  • Discussion of the comparative efficacy of selective versus non-selective ERAs.

Main Results:

  • ET-1 is implicated in the progression of various renal disorders.
  • ERAs have demonstrated potential in improving renal hemodynamics and reducing proteinuria in renoprotection studies.
  • The optimal ERA (selective vs. non-selective) for CKD treatment remains under investigation.

Conclusions:

  • ET-1 antagonism is a potential therapeutic avenue for managing progressive kidney diseases.
  • Combined therapy with ERAs and angiotensin-converting enzyme inhibitors may offer benefits for nephropathies.
  • Further research is required to establish the ideal clinical setting for ET-1 antagonism in CKD management.